Virus-like particles (VLPs) have become key tools in biology, medicine and even
engineering. After their initial use to resolve viral structures at the atomic level, VLPs were …

Virus-like particles (VLPs) have been shown to be strong activators of dendritic cells (DCs).
DCs are the most potent antigen presenting cells (APCs) and their activation prompts the …

Allergen‐specific immunotherapy (AIT) is an allergen‐specific form of treatment for patients
suffering from immunoglobulin E (IgE)‐associated allergy; the most common and important …

Vaccines based on virus-like particles (VLPs) can induce potent B cell responses. Some non-
chimeric VLP-based vaccines are highly successful licensed products (eg, hepatitis B …

Background Peanut allergy is a severe and increasingly frequent disease with high medical,
psychosocial, and economic burden for affected patients and wider society. A causal, safe …

Vaccines need to be rationally designed in order be delivered to the immune system for
maximizing induction of dynamic immune responses. Virus‐like particles (VLPs) are ideal …

The seventh “Future of the Allergists and Specific Immunotherapy (FASIT)” workshop held in
2019 provided a platform for global experts from academia, allergy clinics, regulatory …

Background Allergy to peanut is one of the leading causes of anaphylactic reactions among
food allergic patients. Immunization against peanut allergy with a safe and protective …

Since the introduction of allergen immunotherapy (AIT) over 100 years ago, focus has been
on standardization of allergen extracts, with reliable molecular composition of allergens …

Background Cat allergy in human subjects is usually caused by the major cat allergen Fel d
1 and is found in approximately 10% of the Western population. Currently, there is no …